Impact of Subcutaneous Versus Intramuscular Administration of Inviragen's Live Attenuated Dengue Vaccine on Safety and Immunogenicity
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
Price : $35 *
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Inviragen
- 05 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 15 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.